Related Experiment Videos
Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended
C L Harris1, A S Williams, S M Linton
1Department of Medical Biochemistry, University of Wales College of Medicine, Heath Park, Cardiff, UK. HarrisCL@cardiff.ac.uk
Clinical and Experimental Immunology
|August 8, 2002
Summary
New complement regulatory protein-Ig fusion proteins (CRP-Ig) show potential for treating inflammatory diseases like arthritis. DAF-Ig demonstrated extended circulation and reduced disease severity in rat models, highlighting therapeutic promise.
Area of Science:
- Immunology
- Biotechnology
Background:
- Complement activation drives inflammatory and degenerative diseases.
- Complement regulatory proteins (CRPs) inhibit complement activation.
- Existing soluble CRPs have limitations in therapeutic applications.
Purpose of the Study:
- To develop novel therapeutics based on CRPs.
- To engineer soluble, recombinant CRPs as Fc fusion proteins (CRP-Ig).
- To evaluate the efficacy of DAF-Ig and CD59-Ig in vitro and in vivo.
Main Methods:
- Generation of DAF-Ig, CD59-Ig, and hybrid CRP-Ig fusion proteins.
- In vitro assessment of complement (C) activation inhibition.
- In vivo studies in rats, including pharmacokinetic analysis and arthritis model.
Main Results:
- All generated CRP-Ig reagents inhibited C activation in vitro.
- DAF-Ig exhibited an extended half-life and sustained reduction in plasma complement activity in vivo.
- Intra-articular administration of DAF-Ig significantly reduced arthritis severity in rats.
Conclusions:
- CRP-Ig fusion proteins show potential for sustained therapy in inflammatory disorders.
- DAF-Ig demonstrates therapeutic efficacy in a preclinical arthritis model.
- Careful design of CRP-Ig fusion proteins is crucial for optimal functional activity.